Staar Surgical Company (STAA)
NASDAQ:STAA
Want to see STAA full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.22Last Year’s EPS
-0.34Same Quarter Last Year
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a strong operational and financial turnaround in Q1 2026 highlighted by very strong revenue growth (+119.6% YoY), a return to profitability (adjusted EBITDA $24.4M), improved gross margins (73.6% vs. 65.8%), normalized distributor inventories in China, product launches (EVO+), and scalable Swiss manufacturing to avoid tariffs. Management emphasized cost discipline and a clearer path to sustainable profitability. Offsetting factors include geopolitical and regional headwinds (Middle East, India), near-term pricing pressure (ASP down high single digits), some lingering inventory and higher-cost product roll-through impacts, and conservative disclosure (no formal guidance) due to macro uncertainty and limited near-term visibility. Overall, the positive operational and financial momentum materially outweighs the listed challenges, though dependence on China and macro risks warrant continued monitoring.Company Guidance
Strong Revenue Growth
Net sales of $93.5M in Q1 2026, up 119.6% year-over-year, driven primarily by China; China accounted for $47.4M (~50.7% of total net sales). Excluding China, net sales grew 6% YoY.
Adjusted EBITDA Turned Positive
Adjusted EBITDA of $24.4M in Q1 2026 compared to an adjusted EBITDA loss of $26.3M in the prior-year quarter — a meaningful swing to profitability driven by higher sales and cost actions.
Material Improvement in Profitability and Margins
Gross profit margin improved to 73.6% from 65.8% in the prior-year quarter (+7.8 percentage points). Operating income was $8.0M vs. a loss of $57.4M prior year. Net income was $5.2M ($0.10 diluted EPS) vs. a net loss of $54.2M ($1.10 diluted) in the prior-year quarter.
U.S. Market Progress
U.S. net sales exceeded $6M in Q1 and grew 22% year-over-year. Company received FDA approval expanding EVO ICL indication to ages 45–60, enlarging addressable market.
Product and Manufacturing Milestones
Surpassed 4 million ICLs sold globally. Launched EVO+ ICL in China and began shipping meaningful volumes; early EVO+ demand exceeded expectations. Nidau, Switzerland facility scaling to supply 100% of EVO and EVO+ lenses to China in 2026 to avoid import tariffs.
Inventory Normalization in China
Distributor inventory levels in China normalized and aligned with contractual targets (about six months), with sales to the market approximating end-market sales and inventory levels maintained or slightly reduced during the quarter.
Operating Expense Discipline
Total operating expenses declined to $60.9M from $85.4M year-over-year; excluding restructuring and merger-related costs, OpEx was $51.5M vs. $62.7M prior (-18% YoY). Management re-affirmed a 2026 spending target of $225M.
Strong Cash Position and No Debt
Ended Q1 with $163.9M in cash, cash equivalents and available-for-sale investments and no outstanding debt. Management expects cash build through the remainder of the year after seasonal uses in Q1.
ERP Rollout and Operational Improvements
Oracle ERP rollout progressing with limited disruption to date; focus on scaling Swiss manufacturing and realizing operating leverage from cost reduction efforts initiated in 2025.
STAA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
STAA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2026 | $29.40 | $32.01 | +8.88% |
Mar 03, 2026 | $18.92 | $19.22 | +1.59% |
Nov 05, 2025 | $25.25 | $26.63 | +5.47% |
Aug 06, 2025 | $26.90 | $26.95 | +0.19% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Staar Surgical Company (STAA) report earnings?
Staar Surgical Company (STAA) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Staar Surgical Company (STAA) earnings time?
Staar Surgical Company (STAA) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is STAA EPS forecast?
STAA EPS forecast for the fiscal quarter 2026 (Q2) is 0.22.